Vivo Capital’s Crinetics Pharmaceuticals CRNX Stock Holding History

Vivo Capital’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-350,000	Closed	-$16.4M	–	43
2024 Q1	$16.4M	Hold	350,000	–	–	1.29%	18
2023 Q4	$12.5M	Hold	350,000	–	–	1.02%	20
2023 Q3	$10.4M	Buy	+350,000	New	+$7.21M	1.14%	24
2021 Q4	–	Sell	-517,280	Closed	-$10.9M	–	59
2021 Q3	$10.9M	Sell	517,280 -1,235,066	-70%	-$25.8M	0.49%	36
2021 Q2	$33M	Sell	1,752,346 -461,792	-21%	-$8.11M	1.43%	18
2021 Q1	$33.8M	Sell	2,214,138 -121,751	-5%	-$1.89M	1.19%	19
2020 Q4	$33M	Buy	2,335,889 +72,119	+3%	+$1M	1.47%	14
2020 Q3	$35.5M	Sell	2,263,770 -52,858	-2%	-$808K	2.05%	10
2020 Q2	$40.6M	Sell	2,316,628 -1,004,173	-30%	-$17.1M	2.91%	7
2020 Q1	$48.8M	Buy	+3,320,801	New	+$68.1M	4.42%	5
2019 Q3	–	Sell	-3,375,169	Closed	-$84.4M	–	13
2019 Q2	$84.4M	Hold	3,375,169	–	–	7.91%	2
2019 Q1	$76.8M	Sell	3,375,169 -417,000	-11%	-$10.2M	7.66%	2
2018 Q4	$114M	Hold	3,792,169	–	–	14.52%	2
2018 Q3	$109M	Buy	+3,792,169	New	+$113M	10.95%	2

Other funds holding CRNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vivo Capital's CRNX Position: Q2 2024 in Review

Vivo Capital sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2024, closing a stake of 350,000 shares — an estimated $16.4M sold.

Vivo Capital first reported a position in CRNX in Q3 2018 and held it in 14 quarters. The position peaked at $114M in Q4 2018. 234 funds tracked by Wall St. Rank hold CRNX as of Q2 2024.

Vivo Capital reported no remaining Crinetics Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Vivo Capital sold 350,000 Crinetics Pharmaceuticals shares in Q2 2024, an estimated $16.4M.
Vivo Capital first reported a position in Crinetics Pharmaceuticals in Q3 2018 and held it in 14 quarters.
Vivo Capital's Crinetics Pharmaceuticals position peaked at $114M in Q4 2018.
234 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2024.

Based on Vivo Capital's 13F filing for Q2 2024, filed 14 Aug 2024.